NCT00126646View on ClinicalTrials.gov

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions

LeukemiaLymphoma

Interventions

DRUG

BL22 immunotoxin

PROCEDURE

antibody-drug conjugate therapy

PROCEDURE

immunotoxin therapy

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

Sponsors

Lead Sponsor

All Listed Sponsors

lead

MedImmune LLC

INDUSTRY